Filing Flows › Companies › Zentalis Pharmaceuticals › Report card
Zentalis Pharmaceuticals earnings report card
Every report on file against what analysts and the company itself expected, and what the stock did
Beat rate2 of 3 reports beat the EPS estimate
Zentalis Pharmaceuticals (ZNTL) beat the analysts' EPS estimate in 2 of its last 3 reports (67%), by +6.5% on average. Next report: Nov 10, 2026, analysts expect EPS −$0.52.
Beat rate67% of 3
Average surprise+6.5%
Next reportNov 10, 2026
Report by report
| Quarter | Reported | EPS est. | EPS reported | Surprise |
|---|---|---|---|---|
| Q to Jun 2026 | Aug 6, 2026 | −$0.48 | −$0.59 | -22.9% |
| Q to Dec 2025 | Mar 26, 2026 | −$0.61 | −$0.49 | +19.9% |
| Q to Sep 2025 | Nov 10, 2025 | −$0.48 | −$0.37 | +22.5% |
Estimates and reported EPS are the Street's adjusted figures. No daily prices are on file for these report days, so the stock's moves are not shown.
Charts
The next report: what to expect → Zentalis Pharmaceuticals: every quarter →
Read automatically from SEC filings, earnings releases and public estimates; errors are possible. Not investment advice.